UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file numbe ...

分组1 - Myriad Genetics, Inc. reported a strong earnings beat for Q4 2025, with Non-GAAP EPS at $0.04, surpassing consensus estimates [1] - The stock price increased approximately 25% in pre-market trading following the earnings announcement [1] 分组2 - The article emphasizes the importance of combining scientific expertise with financial analysis in the biotech sector [1] - The focus is on identifying innovative biotechnology companies that are developing unique therapies and technologies [1] - The analysis aims to evaluate the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]

SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular Residual Disease) Test, Prolaris® Prostate Cancer Prognostic Test and MyRisk® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratifi ...

Key Takeaways MYGN reported Q4 adjusted EPS of 4 cents, beating estimates by 350% as shares surged 21.7% after hours.MYGN's revenues of $209.8M topped estimates, driven by gains in cancer and tumor profiling tests.MYGN's gross margin fell to 70%, while 2026 revenue guidance stands at $860M-$880M.Myriad Genetics, Inc. (MYGN) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year. Adjusted earnings exclude am ...

Core Insights - Myriad Genetics reported revenue of $209.8 million for the quarter ended December 2025, a decrease of 0.4% year-over-year, with an EPS of $0.04 compared to $0.03 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $207.59 million by 1.07%, while the EPS surprised positively by 350% against a consensus estimate of -$0.02 [1] Revenue Breakdown - Prenatal revenue was $44.9 million, below the two-analyst average estimate of $47.02 million, showing no year-over-year change [4] - Hereditary Cancer revenue reached $96.8 million, surpassing the average estimate of $94.87 million, reflecting a year-over-year increase of 2.7% [4] - Tumor Profiling revenue was reported at $31.5 million, exceeding the two-analyst average estimate of $28.59 million, with a year-over-year growth of 2.3% [4] Stock Performance - Myriad's shares have declined by 26.9% over the past month, contrasting with a 1.8% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +350.00%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.01 per share when it actually produced break-even earnings, delivering a surprise of +100%.Over the ...

Raha highlighted volume growth in several areas, including MyRisk in oncology, with affected volumes up 14% and unaffected volumes up 11% year-over-year. He also pointed to an acceleration in Prolaris test volume growth to 12% year-over-year in the quarter, which he attributed to actions taken over the past two quarters, including incremental commercial investments focused on urologists.Wheeler said overall test volumes increased 2% year-over-year, while average revenue per test declined 2% year-over-year. ...

Myriad Genetics (NasdaqGS:MYGN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAndrew Cooper - Director of Equity Research for Life Science Tools and Services and Diagnostics and Clinical LaboratoriesBen Wheeler - CFOBrian Donnelly - CCOLu Li - Director of Healthcare Equity ResearchMark Verratti - COOMatt Scalo - SVP of Investor RelationsSam Raha - President and CEOConference Call ParticipantsBill Bonello - Senior Research AnalystDan Brennan - Managing Director and Senior Research A ...

Myriad Genetics (NasdaqGS:MYGN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAndrew Cooper - Director of Equity Research for Life Science Tools and Services and Diagnostics and Clinical LaboratoriesBen Wheeler - CFOBrian Donnelly - CCOLu Li - Director of Healthcare Equity ResearchMark Verratti - COOMatt Scalo - SVP of Investor RelationsSam Raha - President and CEOConference Call ParticipantsBill Bonello - Senior Research AnalystDan Brennan - Managing Director and Senior Research A ...

Myriad Genetics (NasdaqGS:MYGN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker11Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised ...